IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Xenotransplantation: The Current Status and Future Prospective

Miss. Vaishnavi Dilip Dhokane, Dr. Avinash S. Jiddewar, Asst. Prof. Pranit G. Kubare
Miss. Sakshi Vijay Khandare, Mr. Shivam Baburao Waghamare
NSPM College of Pharmacy, Darwha, Yavatmal

Abstract: *Xenotransplantation, the transplantation of living cells, tissues, or organs from one species to another, represents a promising solution to the critical shortage of human donor organs. This comprehensive report examines the current status of xenotransplantation research, focusing on pig-to-human transplants, it includes major immunological barrier and their prevention, current status of xenotransplantation, and future prospective. With advances in clinical applications, xenotransplantation has moved from theoretical possibility to clinical reality, offering hope to thousands of patients on transplant waiting lists worldwide. [1,2]*

Keywords: Xenotransplantation, allotransplantation, global organ crisis, immunological barrier, hyperacute rejection, acute humoral xenograft rejection, cellular xenograft rejection, genetic modification



Fig. 1: Xenotransplantation

I. INTRODUCTION

1.1 The Global Organ Crisis:

The global shortage of human organs for transplantation has reached critical proportions, representing one of the most pressing challenges in modern medicine. According to recent statistics, over 100,000 patients are currently on organ transplant waiting lists in the United States alone, with an average of 17 people dying each day while waiting for an organ.[3]

Worldwide, the situation is even more dire, with millions of patients suffering from end-stage organ failure who lack access to transplantation services entirely. The disparity between organ supply and demand continues to widen. In 2023, approximately 46,000 transplants were performed in the United States, yet the waiting list grew by nearly 15,000 patients. This gap reflects not only the scarcity of donor organs but also improvements in medical care that allow more patients to survive long enough to require transplantation. The median wait time for a kidney transplant now exceeds

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

five years in many regions, during which patients must undergo dialysis a costly, time-consuming and physically demanding treatment that significantly impacts quality of life.

1.2 Historical Context:

The concept of xenotransplantation is not new. Early attempts date back to the early 20th century, when surgeons experimented with transplanting animal organs into hu mans out of desperation. In 1906, Mathieu Jaboulay performed the first documented xenotransplant, grafting pig and goat kidneys into human patients. These early attempts all failed within hours due to what we now understand as hyperacute rejection.

The most famous case remains that of Baby Fae in 1984, an infant born with hypoplastic left heart syndrome who received a baboon heart at Loma Linda University Medical Center. While the infant survived for 21 days longer than any previous xenotransplant recipient the ultimate failure highlighted the formidable immunological barriers that would need to be overcome.[1]

These early failures led to a period of relative dormancy in xenotransplantation research during the late 1980s and early 1990s. However, advances in molecular biology, immunology, and genetic engineering have reignited interest in this field. The successful cloning of Dolly the sheep in 1996 demonstrated the feasibility of creating genetically modified large mammals, opening new possibilities for xenotransplantation.[4]

1.3 The Modern Era:

Today's xenotransplantation research bears little resemblance to early attempts. Modern approaches combine sophisticated genetic engineering, precise immunosuppression protocols, pathogen-free breeding environments, and comprehensive understanding of cross species immunology. The field has evolved from simple organ transplantation attempts to a comprehensive biotechnology enterprise involving gene editing, stem cell research, and advanced immunological manipulation.



Fig. 2: Timeline of major milestones in xenotransplantation research

1.4 Scope of Xenotransplantation:

- **Solid Organ Xenotransplantation**

  The primary scope of xenotransplantation is the transplantation of solid organs such as kidneys, hearts, livers, and lungs from pigs to humans. These organs are lifesaving for patients with end-stage organ failure, providing a

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

critical alternative to human donors. Xenotransplantation offers a potential continuous supply of organs, reducing waiting times and associated mortality. Moreover, solid organ transplants allow physicians to study organ-specific challenges, including metabolic compatibility, vascularization, and long-term function. By focusing on solid organs, the field ensures immediate clinical relevance while informing immunological and surgical strategies for broader applications.

- **Tissue Xenotransplantation**
  Tissue xenotransplantation includes corneas, skin, heart valves, bone, and tendons. These tissues are critical for reconstructive surgery, burn treatment, and organ repair. Unlike solid organs, tissue transplants often have lower immunogenicity, making them easier to manage clinically. This scope allows xenotransplantation to address a wide range of medical needs, from cosmetic reconstruction to functional repair, and helps develop protocols for safe handling, storage, and integration of xenogeneic tissues into human recipients.
- **Clinical Translation and Future Perspectives**
  The ultimate scope is the translation of xenotransplantation from experimental research to clinical practice. This includes establishing standardized surgical protocols, long-term patient monitoring, and integration of new technologies for routine use. Future perspectives involve combining xenotransplantation with regenerative medicine, gene editing, and immune modulation to create sustainable and effective therapies. By focusing on clinical translation, the field ensures that research benefits patients worldwide.[5]
- **Cellular Xenotransplantation**
  Xenotransplantation is not limited to whole organs; it also includes cellular therapy. For instance, pancreatic islet cells can be transplanted to restore insulin production in diabetic patients, while neuronal cells may be used to treat neurodegenerative diseases such as Parkinson's disease. This approach allows targeted intervention, reduces systemic complications, and provides functional improvements without the need for full organ replacement. Cellular xenotransplantation is a platform for testing immune modulation strategies in a controlled setting, offering insights into graft survival and integration.
- **Preclinical Testing in Non-Human Primates**
  Non-human primates provide the most relevant preclinical models for xenotransplantation. Studies in baboons or macaques allow researchers to evaluate organ function, immune rejection, and survival in systems similar to humans. These experiments help optimize immunosuppressive protocols, surgical techniques, and post-transplant care. Preclinical testing also informs risk management strategies, including infection control and long-term graft monitoring, ensuring safer transition to human clinical trials.[6]
- **Immunological Research**
  Understanding immune mechanisms is a critical scope of xenotransplantation. The immune system can recognize animal organs as foreign, leading to hyperacute, acute, or chronic rejection. Investigating these pathways helps design immunosuppressive therapies and tolerance induction methods. Research in this area not only improves graft survival but also enhances our knowledge of transplant immunology, benefiting all types of transplantation.
- **Ethical, Legal, and Social Considerations**
  Ethical, legal, and social concerns are integral to xenotransplantation. These include animal welfare, patient consent, cultural acceptance, and equitable access. Researchers and policymakers must ensure that xenotransplantation adheres to ethical standards while balancing scientific progress and public perception. Addressing these concerns helps build societal trust and facilitates the responsible introduction of xenotransplantation into clinical practice.[7]
- **Infectious Disease Management**
  Xenotransplantation must address the risk of transmitting animal pathogens to humans. Porcine endogenous retroviruses (PERVs) are a major concern, alongside other bacteria or viruses. This scope involves implementing bio secure housing, donor screening, and antiviral strategies to ensure recipient safety and minimize public health risks. A comprehensive infectious disease management program is critical for regulatory approval and long-term clinical adoption.[8]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

- **Genetic Engineering of Donor Animals**
  A major scope is the genetic modification of donor pigs to reduce immune incompatibility and improve graft survival. Techniques such as CRISPR-Cas9 allow the deletion of antigens responsible for hyperacute rejection and insertion of human-compatible genes. This not only enhances the success of solid organ transplants but also facilitates tissue and cellular transplantation. Genetic engineering is essential for reducing immune responses, improving organ function, and enabling clinical translation of xenotransplantation.

II. DONAR SPECIES & GENETIC MODIFICATIONS:

2.1 Why Pigs as Donor Animals?

Among potential donor species, pigs have emerged as the most promising candidates for several compelling reasons. While early xenotransplantation attempts utilized non-human primates, ethical concerns, limited availability, and disease transmission risks have shifted focus almost exclusively to porcine donors.[1]

Physiological Compatibility:

Pigs offer remarkable anatomical and physiological similarities to humans:

- **Organ Size and Structure:** Adult pig organs are comparable in size to human organs, making them suitable for transplantation without significant anatomical modifications. A pig heart weighs approximately 300-350 grams, similar to an adult human heart. Pig kidneys are also appropriately sized, though typically transplanted as pairs due to slightly lower individual nephron counts.
- **Cardiovascular Physiology:** Pigs possess similar blood pressure, heart rate ranges, and cardiac output characteristics to humans. Their coronary artery anatomy closely resembles human patterns, making cardiac xenotransplantation anatomically feasible.
- **Metabolic Functions:** Pig livers perform similar metabolic functions to human livers, including drug metabolism, protein synthesis, and detoxification. This functional compatibility is crucial for considering liver xenotransplantation.
- **Renal Physiology:** Pig kidneys demonstrate similar glomerular filtration rates and tubular functions to human kidneys, making them viable candidates for renal replacement therapy

2.2 Practical and Logistical Advantages:

Beyond physiological compatibility, pigs offer numerous practical benefits:

1) **Reproductive Efficiency:**
   - Large litter sizes (8-12 piglets per litter)
   - Short gestation period (approximately 114 days)
   - Sexual maturity reached at 6-8 months
   - Breeding can occur year-round
   - Enables rapid scaling of donor populations

2) **Husbandry and Management:**
   - Centuries of domestication have created well-established breeding practices
   - Designated pathogen-free (DPF) facilities can be maintained
   - Relatively low cost compared to primate alternatives
   - Well-characterized genetics and physiology
   - Established veterinary protocols

3) **Genetic Modification Amenability:**
   - Successful cloning techniques established
   - CRISPR-Cas9 gene editing highly effective

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

- Multiple genetic modifications can be stacked
- Stable germline transmission of modifications
- Growing library of characterized genetic modifications



Fig. 3: Key advantages of pig as xenotransplantation donors

III. IMMUNOLOGICAL BARRIERS FOR XENOTRANSPLANTATION:

In medicine, some pig-derived materials-like corneas and heart valves-have already been used successfully after being processed. In these cases, the pig cells are first removed, leaving behind only the scaffold (extracellular matrix), which the patient's own cells later grow into. But when it comes to transplanting whole, living pig organs or cells, things are much harder because the immune system strongly rejects them.

Both the innate (natural antibodies, complement proteins, NK cells, macrophages) and adaptive immune system work together in this rejection.

There are three main types of rejection that can happen one after another:

1) Hyperacute rejection (very fast, within minutes to hours)
2) Delayed Xenograft rejection
3) Chronic rejection

On top of this, problems like blood clotting disorders and inflammation add to the difficulty, often leading to graft failure.

3.1 Hyperacute Rejection:

Hyperacute rejection (HAR) is a type of graft rejection that occurs very rapidly, usually within minutes to a few hours after transplantation, and is most often seen in transplants between different species, such as pigs to humans or non-human primates (NHPs). HAR is mainly caused by pre-existing antibodies in the recipient's blood that recognize specific antigens on the donor organ.

The most common antibodies involved are IgM and IgG, which specifically target galactose-α1,3-galactose (α-Gal) residues. These α-Gal molecules are added to proteins and fats by an enzyme called α1,3 galactosyltransferase (α1,3GT), which is present in pigs and some New World monkeys, but absent in humans, Old World monkeys, and apes due to a gene mutation. About 70–90% of the natural antibodies in humans and these primates are directed against α-Gal epitopes.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

When a pig organ is transplanted into a human or NHP, these anti-Gal antibodies bind to α-Gal on the organ's blood vessels. This triggers a cascade called complement activation, leading to the formation of a membrane attack complex (MAC). As a result, the blood vessel lining (endothelium) is destroyed, blood clots form, and the organ suffers from bleeding, tissue death, and necrosis. Additionally, molecules like reactive oxygen species (ROS) and nitric oxide species (NOS) worsen the damage. Microscopically, HAR is characterized by blood vessel destruction, swelling, deposition of antibodies, and clot formation.[9]

- **Preventive Strategies:**

Two main strategies are used to prevent HAR:

1. Genetic modification of pigs to remove the α1,3GT gene (GTKO pigs), preventing α-Gal formation.
2. Adding human complement-regulatory proteins (like hCD46, hCD55, and hCD59) to pig organs to inhibit complement activation.

Studies have shown that hearts from GTKO pigs transplanted into baboons survived significantly longer, with median survival around 78 days. Liver transplants using genetically modified pigs expressing hCD46 or hCD55 combined with GTKO extended graft survival to 7–9 days, compared to less than 3 days for unmodified pig livers.

While these methods reduce HAR and allow the graft to survive beyond 24 hours, rejection can still occur later due to acute humoral xenograft rejection (AHXR) or delayed xenograft rejection (DXR).[10]

3.2 Delayed Xenograft Rejection:

Delayed xenograft rejection (DXR) happens after hyperacute rejection (HAR) and is often referred to in two different ways depending on perspective:

- From a mechanistic view, it is called Acute humoral xenograft rejection (AHXR), because antibodies are the main drivers.
- From a pathological view, it is called Acute vascular xenograft rejection (AVXR), because the injury mainly occurs in the blood vessels.

In AHXR or AVXR, antibodies attack the xenograft's blood vessels, but the complement system has only a minor role compared to HAR.

Some researchers, however, use DXR to describe cell-mediated rejection without the involvement of antibodies or complement. This is called cellular xenograft rejection (CXR).

Because of these differences, the terminology can be confusing. Different studies often use these terms interchangeably, and so far, there is no international consensus on their exact definitions. For the field to move forward, researchers emphasize the need for globally accepted definitions that clearly separate AHXR, AVXR, and CXR.[11]



Fig. 4: Mechanism of rejection during xenotransplantation. (A) Hyperacute rejection, (B) Delayed xenograft rejection (C) Chronic rejection

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

3.2.1 Acute humoral xenograft rejection:

If a xenograft survives the initial hyperacute rejection (HAR), the next challenge is acute humoral xenograft rejection (AHXR). This usually develops within a few days to a few weeks after transplantation.

Histological features:

AHXR is marked by focal ischemia (reduced blood flow), diffuse clotting inside blood vessels (intravascular coagulation), and severe inflammation. Both antibodies and immune cells contribute to activating the graft's blood vessel lining (endothelium), which worsens tissue injury.

Role of antibodies:

- Early studies showed that removing anti-Gal antibodies from baboons could delay AHXR when they received pig organs expressing human complement-regulatory proteins like CD59 and decay accelerating factor (DAF). This demonstrated that Gal-specific antibodies play a role not only in HAR but also in AHXR.
- However, even when α1,3-galactosyltransferase knockout (GTKO) pigs were used (which lack Gal antigens), antibody-mediated rejection still occurred. This revealed that other molecules, called non-Gal antigens, are also responsible.

Non-Gal antigens involved:

- Neu5Gc: A sugar molecule present in pigs but absent in humans due to an evolutionary gene loss. Identified in 2002 as a major exoantigen.
- Sad antigen: A carbohydrate discovered in 1967, produced by the enzyme β4GALNT2. Inactivating this enzyme reduces antibody binding to pig tissues.
- Other targets include GABARAPL1, COX-2, and even cross-reactive swine leukocyte antigens (SLA) with human HLA. These can trigger both antibody and T cell responses.

Mechanisms of injury:

- IgM and IgG antibodies binding to non-Gal antigens trigger the complement cascade, causing vascular damage.
- Antibodies can also cause injury via antibody-dependent cell-mediated cytotoxicity (ADCC).
- Neutrophils, NK cells, and macrophages further amplify inflammation and endothelial injury, although their exact roles are not fully understood.

Pathological findings in AHXR:

- Widespread bleeding inside the graft.
- Tissue death (necrosis) and infarction.
- Thrombosis (clot formation).
- Neutrophil infiltration.
- Heavy deposition of immunoglobulins, complement, fibrin, and platelets.

These changes are very similar to HAR, but they happen more slowly, over days to weeks instead of hours.[12]

3.2.2 Cellular xenograft rejection:

If a xenograft manages to escape both hyperacute rejection (HAR) and acute humoral xenograft rejection (AHXR), rejection can still occur when immunosuppressive therapy is not strong enough. This type is called cellular xenograft rejection (CXR), and it usually develops within days to weeks after transplantation.

CXR is driven by the body's immune cells rather than just antibodies. It can be triggered by both the innate immune system (involving NK cells, macrophages, neutrophils, and dendritic cells) and the adaptive immune system (involving T cells and B cells). Together, these immune responses cause inflammation and ultimately destroy the graft.[13]

Natural killer (NK) cells:

- NK cells are part of the innate immune system and act as the body's "first responders."
- In xenotransplantation, NK cells can recognize pig cells as foreign because of differences in surface molecules (like swine leukocyte antigens, SLA).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

- In xenotransplantation, NK cells can recognize pig cells as foreign because of differences in surface molecules (like swine leukocyte antigens, SLA).
- They also secrete cytokines (like IFN-γ), which amplify inflammation and recruit other immune cells.
- NK cells can be activated through antibody-dependent cell-mediated cytotoxicity (ADCC), where they bind to antibodies already attached to pig antigens, intensifying graft damage.

Macrophages:

- Macrophages are scavenger cells that engulf and digest foreign material, including pig cells.
- In xenotransplantation, they attack the graft by phagocytosis (literally "eating" pig cells).
- They also release inflammatory molecules like TNF-α, IL-1, and ROS (reactive oxygen species), which damage graft tissue.
- Macrophages play a role in chronic rejection by promoting fibrosis and scarring in the transplanted organs.
- Cross-talk between macrophages and T cells further enhances the adaptive immune response, making rejection stronger and longer-lasting.[14]



Fig. 5: Cellular xenograft rejection. (A) Natural killer cells, (B) Macrophages

3.3 Chronic Rejection:

Chronic rejection usually develops months to years after transplantation. It looks very similar to chronic rejection seen in regular human-to-human transplants (allotransplantation).

The main features include:

- Blood vessel damage (thrombotic microangiopathy),
- Overgrowth of endothelial cells lining the blood vessels,
- Narrowing of vessels,
- Fibrosis (scarring) in the tissue,

All of these changes gradually reduce blood flow, leading to loss of graft function and eventual graft failure.

Because only a few long-term xenograft survivors exist so far, the detailed mechanisms of chronic rejection are not fully known. However, scientists believe it is mainly caused by long-term, low-level immune responses combined with molecular incompatibilities between pig and primate proteins, especially those involved in blood clotting systems.[15]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

IV. PREVENTION OF IMMUNOLOGICAL BARRIERS:

Since 2009, researchers have been using genetically modified pigs to make organs more compatible for transplantation across species. New gene-editing tools, such as zinc finger nucleases, TALEN, and CRISPR/Cas9, have made it faster and easier to create pigs with multiple genetic modifications, which helps reduce the risk of the recipient's immune system attacking the graft.

Preventing rejection is a major challenge in xenotransplantation. Immunosuppressive drugs are essential for this purpose. Traditional medications like corticosteroids, tacrolimus, and cyclophosphamide can delay graft failure, especially when used in higher doses. Studies in non-human primates have shown that long-term survival of transplanted kidneys or livers is possible with these conventional therapies. In 2000, a more targeted approach called co-stimulation blockade was introduced by Buhler and colleagues.

This therapy works by interrupting specific immune activation pathways, and it has proven to be more effective than traditional immunosuppressive drugs in preventing organ rejection.

4.1 Immunosuppressive drugs

1. Glucocorticoids

Glucocorticoids are potent immunosuppressive agents widely used to prevent xenograft rejection. They act by inhibiting the activation and proliferation of T-lymphocytes, which are central to graft rejection. These drugs reduce the production of pro-inflammatory cytokines like IL-1, IL-2, TNF-α, and IFN-γ, thereby dampening both innate and adaptive immune responses. Glucocorticoids also decrease the function of antigen-presenting cells, limiting the ability of the recipient's immune system to recognize the xenograft. They stabilize lysosomal membranes, reducing tissue damage caused by inflammatory cells. By suppressing macrophage and neutrophil activity, they minimize early inflammatory injury to the graft. Glucocorticoids promote lymphocyte apoptosis, particularly of activated T cells, further preventing immune-mediated graft destruction. They are often used in combination with other immunosuppressants to achieve synergistic effects and reduce individual drug toxicity. Their rapid onset of action makes them valuable for controlling acute rejection episodes. Overall, glucocorticoids remain a cornerstone in xenotransplantation protocols due to their broad anti-inflammatory and immunosuppressive properties.[16]

2. Calcineurin inhibitors

Two widely used calcineurin inhibitors, cyclosporin and tacrolimus, work by blocking the enzyme calcineurin, which normally activates a protein called NFAT (nuclear factor of activated T cells). By preventing NFAT from entering the nucleus, these drugs stop the transcription of genes that rely on calcineurin. As a result, T cells do not fully mature and produce fewer signaling molecules, such as interleukin-2 (IL-2), which are essential for coordinating immune responses.

2.1 Cyclosporin

Cyclosporine is a cyclic polypeptide composed of 11 amino acids, predominantly hydrophobic in nature. Its discovery in the early 1980s revolutionized the field of transplantation by significantly reducing the incidence of acute rejection episodes. The drug exerts its effects by binding to cyclophilin, forming a complex that inhibits calcineurin activity. This inhibition prevents the dephosphorylation of NFAT (nuclear factor of activated T cells), thereby blocking its nuclear translocation and subsequent transcription of interleukin-2 (IL-2), a key cytokine in T cell activation. Consequently, T cell proliferation and immune responses against the graft are diminished. In preclinical studies involving cardiac xenotransplantation, baboon recipients treated with cyclosporine and steroids achieved a mean graft survival of 77 days without signs of hyperacute rejection or cyclosporine induced malignancies. Similarly, in baboon-to-monkey liver xenotransplantation, two monkeys survived for 91 and 1,076 days, respectively, when cyclosporine was administered post-transplant. Furthermore, clinical observations in cardiac transplantation have indicated that achieving cyclosporine blood levels around 1,000 ng/mL correlates with improved graft survival rates. However, it's important to note that while cyclosporine effectively suppresses acute rejection, its use is associated with potential nephrotoxicity and other side effects, necessitating careful monitoring and dosage adjustments.[17]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

2.2 Tacrolimus

Tacrolimus is a 23-membered macrolide lactone first isolated in 1987 from Streptomyces tsukubai's. It suppresses T cell proliferation by binding to FK506-binding protein (FKBP), which inhibits calcineurin and prevents NFAT from entering the nucleus. This blocks the expression of multiple cytokines, including IL-2, TNF-α, and IFN-γ, ultimately reducing T cell activation. Approved initially for liver transplantation in 1994, tacrolimus is now a cornerstone of immunosuppressive therapy for solid organ transplants, often combined with glucocorticoids. In xenotransplantation models, including pig-to-rat and pig-to-NHP islet transplants, it effectively prevents acute rejection. Tacrolimus is primarily administered orally, has variable bioavailability (5–67%), and a half-life of 3.5–40.5 hours. Its main adverse effects are nephrotoxicity and neurotoxicity, which can be minimized by maintaining stable drug levels, with dosing guided in part by CYP3A5 genotype.[18]

3. Antiproliferative agents

Antiproliferative agents are a class of immunosuppressive drugs that prevent the rapid division and expansion of immune cells, particularly T and B lymphocytes, which play a central role in xenograft rejection. Common drugs in this class include azathioprine, mycophenolate mofetil (MMF), and leflunomide. These agents inhibit nucleotide synthesis or interfere with DNA replication, thereby suppressing lymphocyte proliferation without broadly affecting other cell types. By doing so, they reduce the production of antibodies and cytokines that would otherwise attack the transplanted organ. In xenotransplantation, antiproliferative agents are often used in combination with calcineurin inhibitors and glucocorticoids to achieve synergistic immunosuppression while minimizing the dose-dependent toxicity of individual drugs. For example, mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, preventing guanine nucleotide synthesis, which selectively affects activated lymphocytes, leading to decreased T cell proliferation and reduced antibody-mediated rejection. These drugs are particularly important in preventing both acute and chronic rejection by dampening both cellular and humoral immune responses. Overall, antiproliferative agents are critical for improving graft survival and maintaining long-term function in xenotransplantation settings.[19]

4.2 Genetically modified Donar pig

The success of xenotransplantation has long been hindered by two major problems: immunological rejection and coagulation dysregulation. Early attempts using unmodified pigs faced rapid destruction of the graft due to natural antibodies, complement activation, and thrombotic microangiopathy. To address these barriers, researchers began developing genetically modified pigs as organ sources, marking a turning point in the field.

Since 2009, most advances in xenotransplantation have been made possible by gene-edited pigs. The introduction of powerful molecular tools, particularly CRISPR/Cas9, revolutionized this area by allowing scientists to make multiple, precise genetic edits with relative ease and speed. As a result, pigs with several targeted modifications can now be produced within months, accelerating progress toward clinical trials.

Genetic modification strategies are generally of two types. The first is the deletion of major pig antigens such as α-Gal, Neu5Gc, and Sad that trigger strong human antibody responses. Knocking out the corresponding genes has been shown to markedly reduce antibody binding and early graft destruction. The second strategy is the insertion of human protective genes that help regulate complement activation, inflammation, and coagulation. For example, the expression of human complement-regulatory proteins (CD46, CD55) or anticoagulant molecules (thrombomodulin, EPCR) has improved graft survival in preclinical models.[20]

With the rapid progress of CRISPR-based editing, pigs carrying five or more genetic modifications have already been produced, combining both antigen knockouts and human protective transgenes. These complex "multi-edited pigs" represent an essential step toward clinical xenotransplantation, since they address multiple pathways of rejection and clotting simultaneously. Furthermore, genetic engineering may also be applied to reduce the risk of transmitting porcine endogenous retroviruses (PERVs), adding another layer of safety for future clinical use.

Taken together, genetically engineered pigs now form the backbone of modern xenotransplantation research, offering a practical path toward overcoming historical barriers and moving closer to safe, routine clinical transplantation.[21]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67



Fig. 6: Genetic modification Strategies in Pig for Xenotransplantation

Genetic modification strategies to overcome xenotransplantation barriers:

The figure illustrates the two major approaches used in genetically modifying pigs for xenotransplantation:

1. **Antigen Knockout**
   - Deletion of key pig antigens that are major targets of human natural antibodies:
     - α-Gal (galactose-α-1,3-galactose)
     - Neu5Gc (N-glycolylneuraminic acid)
     - Dsa antigen (β1,4-N-acetylgalactosaminyltransferase 2)
   - Effect: Reduced human antibody binding → decreased complement activation and hyperacute rejection.

2. **Human Transgene Insertion**
   - Introduction of human genes to provide protection against immune and coagulation injury:
     - Complement regulators: hCD46, hCD55, hCD59 → protect against complement mediated lysis.
     - Coagulation regulators: Human thrombomodulin (them), endothelial protein C receptor (her) → reduce thrombotic microangiopathy.
     - Anti-inflammatory genes: HO-1, A20 → reduce graft inflammation.
   - Effect: Better regulation of coagulation and inflammation → improved graft survival.

3. **Combination (Multi-edited Pigs)**
   - Pigs carrying 5–6 edits (triple knockout + human transgenes).
   - Effect: Simultaneous reduction of antibody-mediated rejection and coagulation dysregulation → closer to clinical translation.

Overall outcome: Multi-gene edited pigs show markedly less antibody binding, improved vascular compatibility, and extended graft survival in preclinical non-human primate models.[22]

VI. SELECTION OF THE FIRST PATIENTS:

When clinical trials of xenotransplantation begin, choosing the right patients will be crucial. The first candidates are expected to be people awaiting organ transplants who face particularly high risks. For example, kidney transplant patients who are all sensitized meaning their immune systems are primed to reject most human donor kidneys may

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

benefit from xenotransplantation. Similarly, older patients over 60 years of age often die while waiting for a suitable kidney; receiving a pig kidney could give them more years free from dialysis.

Infants with severe congenital heart disease are another group who could gain from xenotransplantation. For these babies, time is critical, and a pig heart could provide a lifesaving option when no human donor heart is available. Patients with acute liver failure, for whom no other therapy exists, may also receive pig livers as a temporary bridge until a human liver becomes available.

In the case of diabetes, the most suitable candidates are those with "brittle" diabetes patients who suffer from dangerous low blood sugar episodes that they cannot detect. These patients are at constant risk of life-threatening hypoglycemia. Diabetic patients who already have a kidney transplant, or are about to undergo one, may also benefit from pig islet transplantation, since they are already on immunosuppressive therapy, reducing additional treatment concerns.

VII. CURRENT STATUS OF XENOTRANSPLANTATION:

NON-HUMAN PRIMATE:

Studies on xenotransplantation have often been carried out in non-human primates (NHPs), such as baboons and rhesus monkeys. These animals are used because their immune systems share many similarities with humans. While not a perfect match, they are close enough to serve as reliable experimental models. Over time, researchers have gained a great deal of experience working with these primate models, and many important findings have come from such studies.

- **Rationale for NHP models**

  Non-human primates (NHPs), particularly baboons and macaques, serve as the most accurate preclinical models for xenotransplantation due to their physiological and immunological similarities to humans. These models are crucial for evaluating the efficacy and safety of xenografts before clinical application. Unlike rodents, NHPs offer a more human-like immune response, making them ideal for testing immunosuppressive regimens and understanding organ-specific interactions in xenotransplantation.

  The pig-to-NHP model has been foundational in xenotransplantation research for over four decades. Advancements in genetic engineering have enabled the creation of pigs with multiple gene knockouts and human gene insertions, aiming to reduce immunogenicity and improve graft survival. These developments have propelled xenotransplantation from theoretical discussions to tangible clinical trials.

- **Key finding and Survival data**

  Recent studies have demonstrated significant advancements in pig-to-NHP xenotransplantation. For instance, genetically engineered (GE) pig hearts transplanted into baboons have shown life-supporting function for up to 225 days, with a mean survival of 128 ± 36 days. Similarly, pig kidneys transplanted into baboons have achieved extended survival, with some grafts functioning for over 136 days.

  These outcomes underscore the potential of xenotransplantation as a viable solution to the organ shortage crisis. The extended survival times observed in these studies are a testament to the advancements in genetic engineering, immunosuppressive protocols, and surgical techniques.[23]

- **Functional outcomes**

  Functional assessments of xenografts in NHPs have shown promising results. Pig kidneys have demonstrated stable renal function, including consistent urine output and electrolyte balance, indicating successful graft integration. Cardiac xenografts have maintained hemodynamic stability, with normal heart rate and blood pressure profiles, reflecting adequate graft function.

  These functional outcomes are critical for evaluating the long-term viability of xenografts and their potential translation to human patients. The ability to achieve and maintain organ-specific functions in xenografts is a significant milestone in xenotransplantation research.

- **Limitations**

  Despite these advancements, several challenges persist in NHP xenotransplantation studies. Immune-mediated rejection remains a significant hurdle, with episodes of acute cellular rejection and chronic vasculopathy

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

observed in some cases. Additionally, the complexity of immunosuppressive regimens required to prolong graft survival poses risks of infection and malignancy. Ethical considerations regarding the use of NHPs in research also present ongoing debates within the scientific community.

These limitations highlight the need for continued research to refine genetic modifications, immunosuppressive strategies, and surgical techniques. Addressing these challenges is essential for advancing xenotransplantation from preclinical studies to clinical application.[24]

VIII. CLINICAL APPLICATION OF XENOTRANSPLANTATION:

1. Kidney Xenotransplantation

Kidney xenotransplantation represents the most advanced and clinically relevant application due to the increasing prevalence of end-stage renal disease and limited human donor availability. Transplantation of genetically modified porcine kidneys into human recipients has demonstrated restoration of urine output, stabilization of serum electrolytes, and improvement in metabolic homeostasis. These early clinical outcomes confirm surgical feasibility and short-term functional competence, indicating potential utility as permanent grafts or as bridge-to-transplant options for patients awaiting human organs. Continued advancement in gene editing, complement regulation, and stimulation-based immunosuppression is expected to further enhance graft survival and position renal xenotransplantation as a viable therapeutic alternative.

2. Heart Xenotransplantation

Cardiac xenotransplantation has emerged as a potential therapy for patients with terminal heart failure who are ineligible for mechanical circulatory support or human heart allografts. Genetically engineered porcine hearts transplanted into compassionate-use human recipients have demonstrated acceptable hemodynamic performance, adequate coronary perfusion, and temporary restoration of physiological cardiac output. These cases establish foundational evidence for feasibility and provide valuable insight into immunologic and physiologic challenges. Future applications include permanent cardiac replacement, bridge therapy, and pediatric transplantation. Ongoing refinement of donor gene modifications, antiviral strategies, and targeted immunosuppressive regimens is essential for achieving durable long-term xenograft survival.

3. Liver Xenotransplantation

Clinical liver xenotransplantation remains in an investigational phase, primarily due to the liver's complex metabolic, synthetic and immunological functions. However, porcine livers have been successfully used in extracorporeal perfusion systems to support patients with acute liver failure. These systems facilitate temporary detoxification, stabilize metabolic derangements, and maintain coagulation factor synthesis while patients' recovery or human transplantation. Bioartificial liver devices incorporating porcine hepatocytes have produced similar stabilizing effects in ill individuals. Although whole-organ liver xenotransplantation is not yet clinically feasible, ongoing genetic modifications aim to mitigate thrombocytopenia, coagulation dysregulation, and blood-mediated inflammatory reactions.

4. Lung Xenotransplantation

Lung xenotransplantation is challenged by the lung's intrinsic vulnerability to ischemia-reperfusion injury, inflammatory activation, and endothelial dysfunction. While no clinical human lung xenotransplants have yet been performed, preclinical pig-to-primate models demonstrate short-term ventilation adequacy and gas-exchange capability. Potential future applications include temporary xenogeneic lung perfusion systems to support patients with acute respiratory distress syndrome or end-stage pulmonary disease. With advancements in donor genetic modification, complement inhibition, and ex vivo lung perfusion platforms, xenogeneic lungs may eventually serve as bridge-to-transplant organs. Overcoming acute vascular rejection and pulmonary endothelial activation remains critical for clinical translation.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

5. Islet Xenotransplantation

Porcine pancreatic islet xenotransplantation is a promising therapeutic approach for patients with type 1 diabetes mellitus who exhibit unstable glycemic control or experience recurrent severe hypoglycemia. Encapsulated porcine islets, administered without systemic immunosuppression, have demonstrated improved glycemic stability and reduced insulin requirements in early clinical trials. These islets provide physiologically regulated insulin secretion, thereby restoring partial endocrine function. Innovations in microencapsulation materials, gene editing to reduce antigenicity, and strategies to enhance islet survival continue to advance the field. Islet xenotransplantation may ultimately provide a long-term, minimally invasive alternative to whole-organ pancreas transplantation.

IX. ETHICAL CONCERNS, REGULATION AND SOCIAL ACCEPTABILITY:

The use of genetically engineered pigs to provide organs with reduced risk of rejection raises important ethical considerations. Xenotransplantation could help address long waiting times for donor organs, decrease complications from dialysis, and reduce coercion or financial pressures on human donors. However, it also presents unique ethical and cultural challenges. For instance, in some cultures, porcine-derived organs are considered taboo, although exceptions may be made when the transplant is necessary to save a patient's life.

Some people oppose using animals or animal products for ethical, religious, or welfare reasons, and may object to using pigs for xenotransplantation. Others question raising animals solely for organ harvesting, though far fewer pigs would be needed for transplants than are killed for food annually. Patients on dialysis face high mortality about 240 deaths per day in the U.S. highlighting the potential life-saving benefits of xenotransplants. Pigs used as organ donors would need to be kept in sterile, confined conditions to prevent infections, which restricts their natural behaviors. This creates a tension between protecting patient health and respecting animal welfare, a balance that requires careful consideration from all stakeholders.

Another key ethical concern is the risk of transmitting diseases from animals to humans. Pigs can carry viruses such as porcine endogenous retroviruses (PERVs) and Nipah virus, which are harmless to pigs but can cause serious disease in humans, especially when the recipient is immunosuppressed. Some bacteria may also be transmitted and spread in the community. These risks are significantly reduced if donor pigs are raised in sterile, bio secure conditions, and modern molecular techniques, including CRISPR, have even produced pigs with inactivated PERVs, lowering infection risks further.

Public perception adds another layer of ethical complexity. While xenotransplantation fascinates many, societal understanding of the science and its ethical implications is often limited. Bridging the gap between scientific advancements and public awareness requires integrating ethical discussions and social responsibility into scientific education, while also improving general science literacy. Both are ambitious but essential goals for the responsible development of xenotransplantation.[25]

Regulation

Because xenotransplantation involves risks that extend beyond the individual patient such as potential transmission of animal viruses to the wider community it is subject to strict regulatory oversight in most countries.

- **United States:** The Food and Drug Administration (FDA) regulates xenotransplantation under guidelines that require strict screening of source animals, long-term monitoring of recipients, and maintenance of registries to trace potential infections.
- **European Union:** Regulation is coordinated through directives that emphasize biosafety, animal welfare, and ethical considerations, with the European Medicines Agency (EMA) involved in oversight
- **World Health Organization (WHO):** Provides international guidance, encouraging member states to establish national frameworks to ensure ethical practice, biosafety, and public transparency.
- **India and other developing countries:** Formal regulatory frameworks are still emerging, but discussions are ongoing in bioethics and transplant policy groups.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Social Acceptability

The success of xenotransplantation depends not only on scientific progress but also on how society perceives and accepts it. Public attitudes are influenced by cultural, religious, and ethical values. For example, in some communities, the use of pig organs may be considered unacceptable because of religious prohibitions, while in others the idea of genetically engineering animals raises concerns about "playing with nature."

Trust is another central issue: people may be hesitant to accept xenotransplants if they feel the risks of zoonotic infection, long-term safety, or animal welfare are not adequately addressed. Historical experiences, such as the public reaction to early genetically modified foods, show that public perception can significantly influence the adoption of biomedical technologies. Therefore, transparent communication, active involvement of patients, families, and community leaders, and educational efforts are essential to build societal trust and acceptance. [26]

X. FUTURE PROSPECTIVES

Recent advances in xenotransplantation have shown promising results. Hearts from genetically modified pigs have survived for several months in non-human primates, and baboons have maintained pig heart function for up to two months under clinically relevant immunosuppression regimens. While these regimens can be effective, they are often associated with complications such as infections and graft failure. Future clinical trials will likely require strategies that balance efficacy with reduced toxicity, such as genetic modifications of donor organs, encapsulation, or transplantation into immune-privileged sites.

Clinical application may first occur in high-risk situations, such as using pig livers for short-term support in patients with acute liver failure or pig kidneys and hearts as "bridge" therapies until a human organ becomes available. Importantly, current evidence suggests that human anti-HLA antibodies generally do not cross-react with pig antigens, and prior exposure to pig cells does not appear to compromise outcomes of later human transplants.

Moving to clinical trials will require careful adherence to scientific and ethical guidelines. Public acceptance depends on transparent research, peer-reviewed progress, and honest communication of risks and benefits. A major ethical concern is the existence of unregulated, commercially driven xenotransplantation procedures being offered without scientific evidence, which could undermine the credibility of the field. To address this, organizations such as the International Xenotransplantation Association (IXA) and the World Health Organization (WHO) have issued strong recommendations against such unsafe and unjustified practices. [27]

XI. CONCLUSIONS

Xenotransplantation offers a promising approach to address the global shortage of human donor organs. Advances in genetic engineering and modern immunosuppressive therapy have significantly reduced the risk of hyperacute and delayed xenograft rejection. A clearer understanding of immune mechanisms has improved control over T-cell and antibody responses responsible for graft failure. Despite this progress, long-term graft survival and the potential risk of viral transmission from animals to humans remain major challenges. Ethical and biosafety concerns must be carefully evaluated before large-scale human application. Rigorous donor screening and regulated testing are essential to ensure patient safety.

Recent experimental studies in animal models have shown encouraging improvements in graft survival and function. Continued development in gene editing and selective immunosuppression is expected to further enhance outcomes. Collaboration among scientists, clinicians, and ethicists will be key in translating this research into safe clinical practice. With steady progress and strong ethical oversight, xenotransplantation may soon evolve from an experimental concept to a clinical reality. Future studies should focus on achieving long term tolerance and minimizing post-transplant complications.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

REFERENCES

[1] Cooper, D. K., Esker, B., & Textor, A. J. (2020). A brief history of clinical xenotransplantation. International Journal of Surgery, 23, 205-210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454756/

[2] Sykes, M., & Sachs, D. H. (2021). Transplanting organs from pigs to humans.
Science Immunology, 4(41), eaau6298. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939056/

[3] Potts, J. T. (2020). The organ shortage: A national crisis. Journal of American Medical Association, 323(14), 1361-1362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446891/

[4] Esker, B., Cooper, D. K., & Textor, A. J. (2015). The need for xenotransplantation as a source of organs and cells for clinical transplantation. International Journal of Surgery, 23(Pt B), 199-204. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715892/

[5] Esker, B., Estelada, M.B., Hara, H., van der Windt, D.J., Wikstrom, M., Bottino, R. and Cooper, D.K.C. (2012) 'Clinical xenotransplantation: the next medical revolution?', The Lancet, 379(9816), pp. 672–683. https://doi.org/10.1016/S0140-6736(11)61091-X

[6] Iwase, H. and Kobayashi, T. (2015) 'Current status of pig kidney xenotransplantation', International Journal of Surgery, 23, pp. 229–233. https://doi.org/10.1016/j.ijsu.2015.07.721

[7] Griffith, B.P., Goerlich, C.E., Singh, A.K., Rothblatt, M., Lau, C.L., Shah, A., Lorber, M., Grazioli, A., Zaharia, K.K., Hong, S.N., Joseph, S.M., Ayars, D. and Mohiuddin, M.M. (2022) 'Genetically modified porcine-to-human cardiac xenotransplantation', The New England Journal of Medicine, 387, pp. 35–44. https://doi.org/10.1056/NEJMoa2201422

[8] Yamada, K., Sykes, M. and Sachs, D.H. (2014) 'Tolerance in xenotransplantation', Cold Spring Harbor Perspectives in Medicine, 4(12), article a015594.

[9] Mohiuddin, M.M., Corcoran, P.C., Singh, A.K., Thomas, M.L., Clark, T., Lewis, B.G. et al. (2014) 'Genetically engineered pigs and the survival of xenotransplant organs', Journal of Heart and Lung Transplantation, 33(5), pp. S3–S12.

[10] Galilei, U. (2005) 'The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation', Bioclimate, 87(1), pp. 1–9. https://doi.org/10.1016/j.biochi.2004.10.005

[11] Paddler Karavani, V. and Varki, A. (2011) 'Potential impact of the non-human sialic acid N glycolyl neuraminic acid on transplant rejection risk', Xenotransplantation, 18(1), pp. 1–5. https://doi.org/10.1111/j.1399-3089.2010.00601.x

[12] Lu, T., Yang, B., Wang, R. and Qin, C. (2020) 'Xenotransplantation: current status in preclinical research', Frontiers in Immunology, 10, article 3060. https://doi.org/10.3389/fimmu.2019.03060

[13] Seebach, J.D., Cormack, C.A., Germana, S., Leuer, C., Sachs, D.H. and Der Simonian, H. (1997) 'HLACw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells', Journal of Immunology, 159(7), pp. 3655–3661. PMID: 9317166.

[14] Ide, K., Wang, H., Tahera, H., Liu, J., Wang, X., Asahara, T. and Cooper, D.K.C. (2007) 'Role for CD47–SIRPα signaling in xenograft rejection by macrophages', Proceedings of the National Academy of Sciences of the United States of America, 104(12), pp. 5062–5066.

[15] Mohiuddin, M.M., Singh, A.K., Corcoran, P.C., Thomas, M.L., Clark, T., Lewis, B.G. et al. (2018) 'Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs', Transplantation, 102(7), pp. 1128-1137. doi:10.1097/TP.0000000000002092.

[16] Zhou, Q., Li, Y., Wang, Y., Zhang, Y., Geng, Y., Deng, Z., Cheng, X. & Wang, Y. (2022) 'Current status of xenotransplantation research and the strategies for preventing immunological rejection', Frontiers in Immunology, 13, 899657. Doi: https://doi.org/10.3389/fimmu.2022.899657

[17] Koh, J., Hashimoto, K. & Brake, S. (2023) 'Historical review and future of cardiac xenotransplantation', Frontiers in Immunology, 14, article 10244184. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244184/

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

[18] Sanitary, S.A., Byrne, G.W. & McGregor, C.G.A. (2025) 'The evolution of immunosuppressive therapy in pig-to-non-human-primate xenotransplantation', Transplant International, 38, article 13942. Available at: https://www.frontierspartnerships.org/journals/transplant international/articles/10.3389/ti.2024.13942/full

[19] Kawai, T., Cosima, A.B. & Sachs, D.H. (2004) 'Immunologic aspects of xenotransplantation', New England Journal of Medicine, 351(2), pp. 136–145. Available at: https://doi.org/10.1056/NEJMra032153

[20] Lei, T., et al. (2022) 'Genetic engineering of pigs for xenotransplantation to overcome immunological and hemostatic barriers', Frontiers in Immunology, 13, article 9766364. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9766364

[21] Ali, A., et al. (2024) 'What genetic modifications of source pigs are essential in clinical xenotransplantation?', Xenotransplantation, 31(3), e12746. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11652200

[22] Huai, G., et al. (2025) 'The generation and evaluation of TKO/hCD55/them/her (6GE) gene-modified pigs for clinical organ xenotransplantation', Frontiers in Immunology, 16, article 1488552. Available at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1488552/full

[23] Iwase, H., Liu, H., Wikström, M., Zhou, H., Singh, J., Hara, H., Estelada, M., Long, C., Klein, E., Wagner, R., Phelps, C., Ayars, D., Shapiro, R., Humar, A. & Cooper, D.K.C. (2015) 'Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date', Xenotransplantation, 22(4), pp. 302–309. Doi: 10.1111/xen.12174.

[24] Longin, M., Reichart, B., Steen, S., Sjöberg, T., Paskevicius, A., Liao, Q. et al. (2024) 'Progress in Orthotopic Pig Heart Transplantation in Nonhuman Primates', Transplant International, 37, article 13607. doi:10.3389/ti.2024.13607.

[25] Carrier, A.N., Verma, A., Mohiuddin, M., Pascual, M., Müller, Y.D., Longchamp, A., Bhati, C., Buhler, L.H., Maluf, D.G. & Meier, R.P.H. (2022) 'Xenotransplantation: A new era', Frontiers in Immunology, 13, article 900594. Available at: https://doi.org/10.3389/fimmu.2022.900594

[26] Chapman, J.R., Lynch, R.J. & Wong, G. (2016) 'Xenotransplantation: current status and key bioethical issues', Current Opinion in Organ Transplantation, 21(6), pp. 513–519.
Available at: https://doi.org/10.1097/MOT.0000000000000350

[27] Pierson, R.N. III, Dorling, A., Ayars, D., Rees, M.A., Seebach, J.D., Fishman, J.A., Hering, B.J. and Cooper, D.K.C. (2009) 'Current status of xenotransplantation and prospects for clinical application', Xenotransplantation, 16(5), pp. 263–280. Available at: https://doi.org/10.1111/j.1399-3089.2009.00534.x